April 24, 2024
Finance

Stranded by Mint? This Budgeting App Is a Good Replacement

As an avid Mint user for years, I was heartbroken when the popular budgeting app shut down on March 23. I loved its easy navigation, variety of features and unbeatable price of $0. What could I find to take its place? Mint encouraged its users to migrate their data to Credit Karma, which is owned

Read More
Finance

Norwood Financial Corp Reports Mixed Q1 2024 Results Amid Rising Costs and Decreased Net …

Net Income: $4.43M for Q1 2024, down by 23.3% from $5.78M in Q1 2023. Earnings Per Share: Decreased to $0.55 in Q1 2024 from $0.71 in Q1 2023. Total Assets: Increased to $2.26 billion as of March 31, 2024, up from $2.10 billion as of March 31, 2023. Net Interest Income: Dropped to $14.71M in

Read More
Finance

Jones Day hires finance partner from Baker McKenzie in Australia

Jones Day has hired Alastair Gourlay from Baker McKenzie as a partner in its financial markets practice in Sydney. Gourlay is a banking and finance lawyer with more than 20 years of experience representing financial institutions, investors and corporations on complex cross-border leveraged finance, corporate finance, private credit, funds finance and real estate finance deals

Read More
Finance

Tesla stock pops on plans to ramp up affordable car plans

Tesla (TSLA) reported first quarter results that missed analyst estimates on both the top and bottom lines. Adjusted earnings per share of $0.45 fell short of the $0.52 Wall Street was expecting. Revenue of $21.3 billion fell short of the estimated $22.3 billion. Operating income also missed, $1.17 billion versus the $1.53 billion estimate. However,

Read More
Finance

Tesla stock surges as EV-maker will ‘accelerate’ the launch of cheaper cars

Tesla (TSLA) stock jumped in post-market trading after the company said it would accelerate the launch of more affordable vehicles. “We have updated our future vehicle line-up to accelerate the launch of new models ahead of our previously communicated start of production in the second half of 2025,” Tesla said in its first quarter shareholder

Read More
Finance

Payables finance market dips as interest rates, disclosure rules dampen demand

Our privacy commitments This Privacy Policy outlines the information we may collect about you in relation to your use of our websites, events, related publications and services (“personal data”) and how we may use that personal data. It also outlines the methods by which we and our service providers may (subject to necessary consents) monitor

Read More
Finance

Financial results for Q1 2024

Festi hf. Key findings Sale of goods amounted to ISK 32,223 million, compared to ISK 29,484 million in the previous year, an increase of 9.3% between years. Gross profit from sales of goods and services amounted to ISK 7,033 million, an increase of 806 million or 12.9% between years. Profit Margins from sales of goods

Read More
Finance

Klappir hf.: Financial Results 2023

Klappir Grænar Lausnir hf. Klappir Green Solutions: Financial results 2023 Main financial highlights for 2023, in Icelandic krona: Total revenue was 573.5 million compared to 450.7 million in 2022. Operational EBITDA was 97.2 million (16,9%), compared with 31.5 million (7,0%) in 2022. Operational profit was 46.0 million, compared with -36.5 million in 2022. Net profit

Read More
Finance

GM CFO on electric vehicle demand: It will be choppy

With Tesla’s (TSLA) stock price in the tank, General Motors (GM) is sending a signal the pressure may stay on Elon Musk in the months ahead. “EV adoption is going to be choppy, we’ve certainly seen slowing in the growth rates,” GM CFO Paul Jacobson said on Yahoo Finance Live. Jacobson says GM’s retail sales

Read More
Finance

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals, Ltd. – ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $370 – $390 million –– Abiprubart Phase 2b trial in Sjögren’s Disease planned to initiate in 2H 2024 –– Current operating plan expected to remain cash flow positive

Read More